PANTHER THERAPEUTICS


Associated tags: Patient, Pancreatic cancer, Neoplasm, Cancer, Therapy, Oncology, Clinical Trials, Health, Biotechnology, Toxicity, Pharmaceutical industry, Doctor of Philosophy, Panther, Clinical trial, University, Monash University, Safety, Paclitaxel, Pancreas, Pharmaceutical, PTM-101, MD

Locations: MASSACHUSETTS

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors

Retrieved on: 
Friday, April 5, 2024
Oncology, Medical Devices, Health, Surgery, Clinical Trials, Biotechnology, Boston University, Toxicity, Hematology, Genetics, Executive, Monoclonal antibody, Shire (pharmaceutical company), Merck, Acquisition, BMS, Cancer, University, Doctor of Philosophy, Panther, MBA, Marketing, Neoplasm, Therapy, Chemical engineering, Genetics Institute, F-star, FDA, Pharmaceutical industry

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.

Key Points: 
  • PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
  • “John has been an outstanding addition to our Board and management team since joining the company in September.
  • His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
  • During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MBBS, Therapy, Clinical trial, Medical college, Pharmacokinetics, Medical College of Wisconsin, The Alfred Hospital, MIT, Pancreatic cancer, Royal Australasian College of Surgeons, Royal Australasian College, Pancreatic tumor, Cancer, Patient, Monash University, Physician, MD, Senior, Toxicity, FACS, Panther, University, Paclitaxel, Associate, Technology, Peter MacCallum Cancer Centre, Pancreas, Massachusetts Institute of Technology School of Engineering, Safety, Peter, Doctor of Philosophy, Medical imaging, Pharmaceutical industry, PTM-101, PanTher Therapeutics, PTM-101, PANTHER THERAPEUTICS

PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.

Key Points: 
  • PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.
  • Pancreatic cancer has one of the poorest prognoses of all malignancies, and responses to currently available systemic therapies are inadequate.
  • This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma.
  • PanTher Therapeutics (PanTher) is a clinical-stage oncology company revolutionizing cancer care with a proprietary treatment platform designed to enhance therapeutic response while minimizing side effects.

PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board

Retrieved on: 
Wednesday, August 4, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Gastroenterology

The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board, composed of key opinion leaders with specific expertise in pancreatic cancer and other solid tumors.

Key Points: 
  • The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board, composed of key opinion leaders with specific expertise in pancreatic cancer and other solid tumors.
  • Dr. Pipas, a veteran gastrointestinal (GI) oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization, will direct PanThers clinical development programs.
  • Dr. Clancy is also an Assistant Professor of Surgery at Harvard Medical School, where he received his Doctor of Medicine.
  • Timothy B. Gardner, MD, is Director of the Gastroenterology & Hepatology Fellowship Program and Director of Pancreatic Disorders at Dartmouth-Hitchcock Medical Center.

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, June 17, 2021
Research, Finance, Clinical trials, Professional services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Oncology, Pancreatic cancer

The Series A round brings the total amount raised by the company to $7.4M.

Key Points: 
  • The Series A round brings the total amount raised by the company to $7.4M.
  • PanThers novel approach empowers oncologists to treat patients with life-threatening cancers by unlocking a drugs full potential through direct, sustained treatment at the tumor site.
  • PanTher Therapeutics (PanTher) is a privately held oncology company revolutionizing cancer care with a proprietary treatment platform designed to enhance therapeutic response while minimizing side effects.
  • PanTher is currently investigating the platform for the treatment of solid tumors, and the company is gearing up to initiate its first clinical trial for its lead indication, pancreatic cancer.